These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1330 related items for PubMed ID: 23849704

  • 1. Tissue-selective estrogen complexes for postmenopausal women.
    Mirkin S, Komm BS.
    Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
    [Abstract] [Full Text] [Related]

  • 2. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.
    Komm BS, Mirkin S, Jenkins SN.
    Steroids; 2014 Nov; 90():71-81. PubMed ID: 24929044
    [Abstract] [Full Text] [Related]

  • 3. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
    Pickar JH, Mirkin S.
    Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
    [Abstract] [Full Text] [Related]

  • 4. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
    Pinkerton JV, Pickar JH, Racketa J, Mirkin S.
    Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
    [Abstract] [Full Text] [Related]

  • 5. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.
    Abraham L, Pinkerton JV, Messig M, Ryan KA, Komm BS, Mirkin S.
    Maturitas; 2014 Jul; 78(3):212-8. PubMed ID: 24837362
    [Abstract] [Full Text] [Related]

  • 6. Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model.
    Pinkerton JV, Komm BS, Mirkin S.
    Climacteric; 2013 Dec; 16(6):618-28. PubMed ID: 23805785
    [Abstract] [Full Text] [Related]

  • 7. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G, Bobula J, Mirkin S.
    Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
    [Abstract] [Full Text] [Related]

  • 8. Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide.
    Palacios S, Currie H, Mikkola TS, Dragon E.
    Maturitas; 2015 Apr; 80(4):435-40. PubMed ID: 25684082
    [Abstract] [Full Text] [Related]

  • 9. The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.
    Kagan R.
    J Womens Health (Larchmt); 2012 Sep; 21(9):975-81. PubMed ID: 22759213
    [Abstract] [Full Text] [Related]

  • 10. Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms.
    Mirkin S, Ryan KA, Chandran AB, Komm BS.
    Maturitas; 2014 Jan; 77(1):24-31. PubMed ID: 24246155
    [Abstract] [Full Text] [Related]

  • 11. Selective estrogen modulators in menopause.
    Gambacciani M.
    Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250
    [Abstract] [Full Text] [Related]

  • 12. Advances in menopausal therapy: the tissue-selective estrogen complex.
    Moore A.
    J Am Assoc Nurse Pract; 2013 Mar; 25(3):126-33. PubMed ID: 24218199
    [Abstract] [Full Text] [Related]

  • 13. Bazedoxifene and Conjugated Equine Estrogen: A Combination Product for the Management of Vasomotor Symptoms and Osteoporosis Prevention Associated with Menopause.
    Umland EM, Karel L, Santoro N.
    Pharmacotherapy; 2016 May; 36(5):548-61. PubMed ID: 27027527
    [Abstract] [Full Text] [Related]

  • 14. Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.
    Pinkerton JV, Stovall DW.
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1613-21. PubMed ID: 21073353
    [Abstract] [Full Text] [Related]

  • 15. Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes.
    Smith CL, Santen RJ, Komm B, Mirkin S.
    Breast Cancer Res; 2014 Jun 18; 16(3):212. PubMed ID: 25928299
    [Abstract] [Full Text] [Related]

  • 16. Treating menopausal symptoms with a tissue-selective estrogen complex.
    Levine JP.
    Gend Med; 2011 Apr 18; 8(2):57-68. PubMed ID: 21536225
    [Abstract] [Full Text] [Related]

  • 17. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
    Parish SJ, Gillespie JA.
    Postgrad Med; 2017 Apr 18; 129(3):340-351. PubMed ID: 28132583
    [Abstract] [Full Text] [Related]

  • 18. Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy.
    Sharifi M, Lewiecki EM.
    Expert Rev Clin Pharmacol; 2014 May 18; 7(3):281-91. PubMed ID: 24580081
    [Abstract] [Full Text] [Related]

  • 19. Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause.
    Tella SH, Gallagher JC.
    Expert Opin Pharmacother; 2013 Dec 18; 14(17):2407-20. PubMed ID: 24093499
    [Abstract] [Full Text] [Related]

  • 20. Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms.
    Stovall DW.
    Curr Opin Investig Drugs; 2010 Apr 18; 11(4):464-71. PubMed ID: 20336595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 67.